Abstract: Disclosed herein are methods of treating a disease in a subject which is the consequence of previous exposure of the subject to a virus, particularly SARS-CoV-2, the method comprising administration of an effective amount of one or more agents to the subject.

Abstract: Disclosed herein are methods of treating a disease in a subject which is the consequence of previous exposure of the subject to a virus, particularly SARS-CoV-2, the method comprising administration of an effective amount of one or more agents to the subject.

Abstract: Disclosed herein are methods of treating a disease in a subject which is the consequence of previous exposure of the subject to a virus, particularly SARS-CoV-2, the method comprising administration of an effective amount of one or more agents to the subject.

Abstract: Provided herein is a method for treating cancer in a patient in need thereof, wherein said cancer has a tumor proportion score (TPS) for programmed death receptor-1 (PD-1) or programmed death-ligand-1 (PD-L1) of 50% or less and said patient is negative for lymphatic dysfunction, comprising administering a therapeutically effective amount of an antagonist for immune checkpoint inhibition.

Abstract: Provided herein is a method for treating cancer in a patient in need thereof, wherein said cancer has a tumor proportion score (TPS) for programmed death receptor-1 (PD-1) or programmed death-ligand-1 (PD-L1) of 50% or less and said patient is negative for lymphatic dysfunction, comprising administering a therapeutically effective amount of an antagonist for immune checkpoint inhibition.

Abstract: Provided herein is a method for determining cancer treatment using an immune-modulating therapy in a subject in need thereof. The method comprises assessing whether a lymphatic system in a subject is dysregulated. When the lymphatic system is dysregulated, a treatment for the lymphatic system is determined before a therapeutic amount of an immune-modulating therapy is administered to treat cancer in the subject. Alternatively, when the lymphatic system is dysregulated, an immune-modulating therapy is selected to treat cancer in the subject. The immune-modulating therapy is independent of immune-cell priming, antigen trafficking, antigen presentation, and any combination thereof. The subject may also be treated for cancer accordingly.

Abstract: Provided herein is a method for treating cancer in a patient in need thereof, wherein said cancer has a tumor proportion score (TPS) for programmed death receptor-1 (PD-11) or programmed death-ligand-1 (PD-L1) of 50% or less and said patient is negative for lymphatic dysfunction, comprising administering a therapeutically effective amount of an antagonist for immune checkpoint inhibition.

Abstract: Provided herein is a method for determining cancer treatment using an immune modulating therapy in a subject in need thereof. The method comprises assessing whether a lymphatic system in a subject is dysregulated. When the lymphatic system is dysregulated, a treatment for the lymphatic system is determined before a therapeutic amount of an immune modulating therapy is administered to treat cancer in the subject. Alternatively, when the lymphatic system is dysregulated, an immune modulating therapy is selected to treat cancer in the subject, which immune modulating therapy is independent of immune-cell priming, antigen trafficking, antigen presentation, and any combination thereof. The subject may also be treated for cancer accordingly.

Abstract: Provided herein is a method for determining cancer treatment using an immune modulating therapy in a subject in need thereof. The method comprises assessing whether a lymphatic system in a subject is dysregulated. When the lymphatic system is dysregulated, a treatment for the lymphatic system is determined before a therapeutic amount of an immune modulating therapy is administered to treat cancer in the subject. Alternatively, when the lymphatic system is dysregulated, an immune modulating therapy is selected to treat cancer in the subject, which immune modulating therapy is independent of immune-cell priming, antigen trafficking, antigen presentation, and any combination thereof. The subject may also be treated for cancer accordingly.

Abstract: A method for constructing an association map between imaging features and biological data is described. The method comprises combining one or more image features relating to a clinical subject with biological data and using an algorithm to make predictions based on the features and data.